We describe a case of disseminated nocardiosis in a 53-year-old male allogeneic marrow recipient with chronic GVHD, 15 years post BMT. Six months prior to admission he was treated for recurrent chronic GVHD with corticosteroids with a good response. He deteriorated subsequently while still on steroids requiring admission for fever, anorexia, weight loss, productive cough and progressive dyspnoea. On admission he had multiple nodular lesions on chest roentgenogram and subsequently grew Nocardia farcinica in blood culture. N. farcinica is rare post BMT, has a high mortality, is resistant to various antibiotics and needs prolonged antimicrobial therapy. We report the successful management of our patient with single agent trimethoprimsulphamethoxazole.
Nocardia is an aerobic actinomycete commonly found in soil, and infects humans predominantly through the respiratory tract. Amongst Nocardia, N. farcinica is increasingly being recognised as a distinct subgroup of N. asteroides with a high resistance to antibiotics and high mortality. Very few cases of N. farcinica infection have been reported in the literature and it is very rarely cultured in the blood. However, it can cause disseminated disease, especially in the immunocompromised host. We report a bone marrow transplant (BMT) patient with chronic graft-versus-host disease (GVHD) who subsequently developed disseminated N. farcinica infection with pulmonary involvement, and was successfully treated with oral trimethoprim-sulphamethoxazole (TMP/SMX).
Case report
A 53-year-old man with relapsed AML (FAB M3) underwent an allogeneic HLA-matched sibling BMT in December 1982 with TBI-cyclophosphamide as conditioning regimen. His post-BMT course was complicated by acute skin GVHD grade II which resolved with prednisolone. This was ceased 6 months later. In 1990, he was diagnosed to have an anthracycline-induced cardiomyopathy with congestive cardiac failure which was managed with an ACE inhibitor. He was also noted to be hepatitis C antibody positive.
Six months prior to admission, he developed clinical features of chronic GVHD (sicca syndrome, severe weight loss, anorexia and strongly positive antinuclear antibody to double-stranded DNA). Treatment with prednisolone 1 mg/kg/day resulted in rapid improvement, with subsequent tapering to a maintenance dose of 10 mg daily. However, 3 weeks prior to admission, the patient deteriorated with a productive cough, dyspnoea and pleuritic chest pain. On admission he had high fever with a respiratory rate of 60/min and brown sputum.
Chest examination revealed bilateral, scattered coarse crepitations with widespread bronchial breathing. Cardiovascular and neurological examination were normal. No skin lesions were seen. There was oral candidiasis. A chest radiograph showed bilateral widespread nodular opacification varying between 1 and 3.5 cm in size without calcification ( Figure 1a ). A few of these had cavitation, confirmed on CT scan of the chest (Figure 1b ). CT scan of the brain was normal.
The patient was started on intravenous amphotericin and ceftriaxone with gentamicin. Sputum showed a moderate growth of candida. He had a neutrophilic leucocytosis (ANC 11.4 × 10 9 /l ). Four days later, the blood culture grew N. farcinica by the Bactec 9240 System (Becton Dickinson Diagnostic Instruments Systems, Sparks, MD, USA) on two successive blood samples. Antibiotic sensitivity done by the disc-diffusion method showed Nocardia to be sensitive to sulphamethoxazole only and resistant to ampicillin, cefotaxime, ciprofloxacin and erythromycin. There was no growth of any other organism. The patient was started on high-dose TMP/SMX (640/3200 mg daily), with subsequent withdrawal of antibiotics and antifungal agents. He made a rapid recovery 10 days after starting this therapy. Six months after diagnosis on the same dose of TMP/SMX, he remains afebrile with an almost clear chest X-ray. 
Discussion
Nocardia are gram-positive, non-sporing rods causing opportunistic infection in immunocompromised hosts, commonly through the respiratory tract.
1 Among the Nocardia family, N. asteroides is the most pathogenic, of which the most resistant and virulent subgroup is N. farcinica, with over 50% of patients presenting with disseminated infection. 2 The overall incidence of nocardiosis was found to be 0.7% in a series of over 800 BMT recipients 3 and N. farcinica was not isolated in any of them. However, due to the routine use of trimethoprim-sulphamethoxazole for Pneumocystis carinii pneumonia (PCP) prophylaxis, the incidence of nocardiosis may be lower than expected.
Blood cultures are rarely positive in N. farcinica infections with very few cases being reported in the literature. One case had disseminated infection with cerebral abscess and was cured with oral antibiotic therapy, 4 another had nocardial endocarditis of an aortic valve prosthesis and did well with a combination of imipenem and amikacin followed by oral TMP-SMX 5 and the third study showed that out of 29 isolates in a group of immunocompromised patients, four isolates were obtained from post-mortem blood culture, of which only one was N. farcinica. 6 N. farcinica bacteraemia has a propensity for causing disseminated disease commonly involving lungs, brain and subcutaneous tissue. Our patient had a pulmonary presentation on admission and chest X-ray as well as CT scan of the chest showed multiple nodular cavitatory lesions. A search for other sites of involvement including CT scan of brain was negative.
Trimethoprim/sulphamethoxazole is the drug of choice in Nocardiosis based on the in vitro synergy of the two agents against this infection, their excellent penetration and good serum levels with oral administration if well tolerated by the patient. 7, 8 Our patient tolerated 640/3200 mg trimethoprim-sulphamethoxazole in daily divided doses and was discharged on the same after clinical improvement over the next 10 days. A chest X-ray 6 months after effective therapy showed almost complete resolution of the chest lesions, except for a small nodule in the right midzone (Figure 2 ).
Other antibiotics which can be used are imipenem, amikacin, ciprofloxacin and cefotaxime. In selecting antimicrobial therapy, identification of the species of nocardia is important. Amongst N. farcinica, the incidence of resistance to imipenem is 36%, the highest reported in the literature, 64-86% to third-generation cephalosporins, 32% to ciprofloxacin and 7% to TMP-SMX. All were susceptible to amikacin but resistant to ampicillin, cefixime and tobramycin. 9 Also, our patient was on prednisolone for the 6 months prior to admission for chronic GVHD. Steroids could have been an added risk factor towards predisposition to this infection. 10 Infections caused by nocardiosis can pose diagnostic problems, are associated with a high degree of mortality, require a high index of clinical suspicion and prolonged antimicrobial therapy. This case report illustrates that even if the patient has disseminated disease, prompt recognition of the organism and specific therapy even with a single agent as in our case, can successfully treat this infection. Nocardiosis must be considered in the differential diagnosis in immunocompromised hosts with atypical chest lesions, especially in the setting of GVHD and concomitant steroid therapy.
The patient described in this report is unusual because of the length of time between transplantation and development of chronic GVHD and opportunistic infection. In this case, the diagnosis of chronic GVHD was primarily clinical without biopsy evidence. It cannot be excluded that the clinical syndrome observed initially was due to an autoimmune disturbance resulting from chronic hepatitis C infection. Nevertheless, the disseminated Nocardia infection appears to have resulted from immune deficiency secondary to immunosuppressive therapy and chronic GVHD.
